Dividend Details for H.B. Fuller: Key Insights Before the Oct 16, 2025 Ex-Dividend Date

H.B. Fuller (FUL) has recently announced a cash dividend of $0.23500000 per share, set to be paid on Oct 30, 2025, with an ex-dividend date of Oct 16, 2025. Investors who purchase the stock after this date will not be eligible for the upcoming payout. The announcement was made on Oct 2, 2025, and this dividend amount is significantly higher than the average of the last 10 dividends, which stood at $0.12834066 per share. The company has a consistent history of cash dividends, with the last one issued on Aug 14, 2025, also at $0.23500000 per share, highlighting its current stable payout pattern. Investors should note that the ex-dividend date is the last opportunity to buy shares and receive the dividend for this cycle.

Over the past week, H.B. Fuller has made several strategic announcements that could influence its stock performance and long-term direction. Most notably, the company recently appointed Celine Martin, a veteran with over 30 years of global MedTech experience, to its Board of Directors, effective Dec 1, 2025. Martin brings deep expertise in medical devices, having led cardiovascular and surgical instrument divisions at Johnson & Johnson. Her addition to the Audit and Compensation Committees is expected to strengthen corporate oversight and support the company’s growth ambitions in the medical adhesives market, a sector projected to expand at an 8.3% CAGR. Analysts have noted that her background aligns well with H.B. Fuller’s strategic focus on expanding into high-growth healthcare segments.

Since the last update, H.B. Fuller has also taken steps to reinforce its board structure and governance practices. Martin’s appointment includes a compensation package featuring a $100,000 annual cash retainer, 1,300 restricted stock units, and a potential discretionary phantom stock award valued at $165,000. The board emphasized that Martin has no material interest in customer or supplier relationships with Johnson & Johnson, ensuring her independence. The board size will increase to nine members, with eight being independent, a move that analysts suggest will enhance transparency and accountability in leadership decisions.

As of late, the company’s recent board additions and strategic focus on the medical market have drawn attention from investors and industry observers. With the ex-dividend date of Oct 16, 2025, fast approaching, shareholders are advised to consider both the dividend opportunity and the evolving corporate strategy when evaluating their investment positions. The ex-dividend date is the final day to purchase the stock and qualify for the upcoming dividend, with any transactions after this date forfeiting the payout.